The European Commission has granted approval to Santen\u2019s Ryjunea for the management of childhood myopia.<\/p>\n
A statement from Santen highlighted that the 0.1mg\/ml atropine eye drop has received approval for children between the ages of three and 14 at the initiation of treatment with myopia progression of 0.5 D or more per year and a severity of -0.5 D to -6.0 D.<\/p>\n
The approval follows results from the Phase III STAR study, which found that Ryjunea reduced annual progression of myopia by 30% over two years when compared to a control group. The study also reported that the eye drop had a favourable safety and tolerability profile.<\/p>\n
Santen chief medical officer, Peter Sallstig, highlighted: \u201cWe believe that a clinically-proven and regulatory-approved, low-dose atropine will be an important component of a comprehensive strategy for myopia control in children.\u201d<\/p>\n
He observed that watching a child\u2019s myopia worsen year after year can be \u201cdeeply worrying\u201d for families.<\/p>\n
\u201cRyjunea offers the opportunity to act early. As a low-dose atropine eye drop, administered once daily at bedtime, it provides a convenient way to manage myopia that integrates easily into a child\u2019s routine,\u201d Sallstig said.<\/p>\n","protected":false},"excerpt":{"rendered":"The European Commission has granted approval to Santen\u2019s Ryjunea for the management of childhood myopia. A statement from…\n","protected":false},"author":2,"featured_media":177149,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[73104,2557,105,4326,68120,49644,49643,73105,73103,16,15],"class_list":{"0":"post-177148","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-atropine","9":"tag-european-commission","10":"tag-health","11":"tag-medication","12":"tag-myopia","13":"tag-optometry-today","14":"tag-ot","15":"tag-ryjunea","16":"tag-santen","17":"tag-uk","18":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114667821711456353","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/177148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=177148"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/177148\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/177149"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=177148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=177148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=177148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}